The therapeutic potential of human multipotent mesenchymal stromal cells combined with pharmacologically active microcarriers transplanted in hemi-parkinsonian rats

Biomaterials

Volumn 32, Issue 6, 2011, Pages 1560-1573

  Delcroix, Gaëtan J R ^a,b   Garbayo, Elisa ^a,b   Sindji, Laurence ^a,b   Thomas, Olivier ^a,b   Vanpouille Box, Claire ^a,b   Schiller, Paul C ^c,d   Montero Menei, Claudia N ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Laminin; Mesenchymal stromal cells; Neurotrophin 3; Parkinson's disease; Pharmacologically active microcarriers; Tissue engineering

Indexed keywords

LAMININ; MESENCHYMAL STROMAL CELLS; MICROCARRIERS; NEUROTROPHIN 3; PARKINSON'S DISEASE;

AMINO ACIDS; BIOMIMETICS; CELL CULTURE; DISEASES; FLOWCHARTING; PEPTIDES; RATS; TISSUE; TISSUE ENGINEERING;

CELLS;

AMPHETAMINE; CHEMOKINE; GROWTH FACTOR; LAMININ; MICROSPHERE; NEUROTROPHIN 3; POLYGLACTIN; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABILITY; BIOMIMETICS; BONE MARROW CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL ISOLATION; CELL SUBPOPULATION; CELL THERAPY; CELL TRANSPLANTATION; CIRCLING BEHAVIOR; COMPLEX FORMATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOMODULATION; IN VITRO STUDY; MESENCHYMAL STEM CELL; MICROCARRIER CULTURE; MULTIPOTENT STEM CELL; NERVE CELL; NERVE CELL DIFFERENTIATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TISSUE ENGINEERING;

ANIMALS; BEHAVIOR, ANIMAL; CELL DIFFERENTIATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LACTIC ACID; LAMININ; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROSPHERES; MULTIPOTENT STEM CELLS; NEUROTROPHIN 3; PARKINSON DISEASE; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; STROMAL CELLS; TISSUE ENGINEERING;

PARKINSONIA; RATTUS;

EID: 78650268454     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.041     Document Type: Article

References (69)

1. Papa S.M., Engber T.M., Kask A.M., Chase T.N. Motor fluctuations in levodopa treated Parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994, 662:69-74.
2. Fahn S. Is levodopa toxic?. Neurology 1996, 47:S184-S195.
3. Drucker-Colin R., Verdugo-Diaz L. Cell transplantation for Parkinson's disease: present status. Cell Mol Neurobiol 2004, 24:301-316.
4. Lindvall O., Hagell P. Role of cell therapy in Parkinson's disease. Neurosurg Focus 2002, 13:e2.
5. Delcroix G.J.R., Schiller P.C., Benoit J.-P., Montero-Menei C.N. Adult cell therapy for brain neuronal damages and the role of tissue engineering. Biomaterials 2010, 31:2105-2120.
6. Lindvall O., Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol Sci 2009, 30:260-267.
7. Schierle G.S., Hansson O., Leist M., Nicotera P., Widner H., Brundin P. Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nat Med 1999, 5:97-100.
8. Kordower J.H., Rosenstein J.M., Collier T.J., Burke M.A., Chen E.Y., Li J.M., et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1996, 370:203-230.
9. Kordower J.H., Freeman T.B., Chen E.Y., Mufson E.J., Sanberg P.R., Hauser R.A., et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 1998, 13:383-393.
10. Brundin P., Barbin G., Isacson O., Mallat M., Chamak B., Prochiantz A., et al. Survival of intracerebrally grafted rat dopamine neurons previously cultured in vitro. Neurosci Lett 1985, 61:79-84.
11. Delcroix G.J., Curtis K.M., Schiller P.C., Montero-Menei C.N. EGF and bFGF pre-treatment enhances neural specification and the response to neuronal commitment of MIAMI cells. Differentiation 2010, 80:213-227.
12. Hermann A., Liebau S., Gastl R., Fickert S., Habisch H.J., Fiedler J., et al. Comparative analysis of neuroectodermal differentiation capacity of human bone marrow stromal cells using various conversion protocols. J Neurosci Res 2006, 83:1502-1514.
13. Ross J.J., Verfaillie C.M. Evaluation of neural plasticity in adult stem cells. Philos Trans R Soc Lond B Biol Sci 2008, 363:199-205.
14. Song S., Sanchez-Ramos J. Brain as the Sea of Marrow. Exp Neurol 2003, 184:54-60.
15. Morikawa S., Mabuchi Y., Niibe K., Suzuki S., Nagoshi N., Sunabori T., et al. Development of mesenchymal stem cells partially originate from the neural crest. Biochem Biophys Res Commun 2009, 379:1114-1119.
16. Tatard V.M., D'Ippolito G., Diabira S., Valeyev A., Hackman J., McCarthy M., et al. Neurotrophin-directed differentiation of human adult marrow stromal cells to dopaminergic-like neurons. Bone 2007, 40:360-373.
17. Barzilay R., Kan I., Ben-Zur T., Bulvik S., Melamed E., Offen D. Induction of human mesenchymal stem cells into dopamine-producing cells with different differentiation protocols. Stem Cells Dev 2008, 17:547-554.
18. Trzaska K.A., Kuzhikandathil E.V., Rameshwar P. Specification of a dopaminergic phenotype from adult human mesenchymal stem cells. Stem Cells 2007, 25:2797-2808.
19. Wolff EF, Gao XB, Yao KV, Andrews ZB, Du H, Elsworth JD, et al. Endometrial stem cell transplantation restores dopamine production in a Parkinson's disease model. J Cell Mol Med. 2010, doi: 10.1111/j.1582-4934.2010.01068.x.
20. Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003, 5:485-489.
21. Nasef A., Mathieu N., Chapel A., Frick J., Francois S., Mazurier C., et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007, 84:231-237.
22. Delcroix G.J., Jacquart M., Lemaire L., Sindji L., Franconi F., Le Jeune J.J., et al. Mesenchymal and neural stem cells labeled with HEDP-coated SPIO nanoparticles: in vitro characterization and migration potential in rat brain. Brain Res 2009, 1255:18-31.
23. Mahmood A., Lu D., Wang L., Chopp M. Intracerebral transplantation of marrow stromal cells cultured with neurotrophic factors promotes functional recovery in adult rats subjected to traumatic brain injury. J Neurotrauma 2002, 19:1609-1617.
24. Sykova E., Jendelova P. In vivo tracking of stem cells in brain and spinal cord injury. Prog Brain Res 2007, 161:367-383.
25. Jendelova P., Herynek V., Urdzikova L., Glogarova K., Kroupova J., Andersson B., et al. Magnetic resonance tracking of transplanted bone marrow and embryonic stem cells labeled by iron oxide nanoparticles in rat brain and spinal cord. J Neurosci Res 2004, 76:232-243.
26. Hellmann M.A., Panet H., Barhum Y., Melamed E., Offen D. Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett 2006, 395:124-128.
27. Bouchez G., Sensebe L., Vourc'h P., Garreau L., Bodard S., Rico A., et al. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Neurochem Int 2008, 52:1332-1342.
28. Sadan O., Bahat-Stromza M., Barhum Y., Levy Y.S., Pisnevsky A., Peretz H., et al. Protective effects of neurotrophic factors secreting cells in a 6OHDA rat model of Parkinson disease. Stem Cells Dev 2009, 18:1179-1190.
29. Levy Y.S., Bahat-Stroomza M., Barzilay R., Burshtein A., Bulvik S., Barhum Y., et al. Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy 2008, 10:340-352.
30. McCoy M.K., Martinez T.N., Ruhn K.A., Wrage P.C., Keefer E.W., Botterman B.R., et al. Autologous transplants of Adipose-Derived Adult Stromal (ADAS) cells afford dopaminergic neuroprotection in a model of Parkinson's disease. Exp Neurol 2008, 210:14-29.
31. Orive G., Anitua E., Pedraz J.L., Emerich D.F. Biomaterials for promoting brain protection, repair and regeneration. Nat Rev Neurosci 2009, 10:682-692.
32. Saporta S., Borlongan C., Moore J., Mejia-Millan E., Jones S.L., Bonness P., et al. Microcarrier enhanced survival of human and rat fetal ventral mesencephalon cells implanted in the rat striatum. Cell Transplant 1997, 6:579-584.
33. Borlongan C.V., Saporta S., Sanberg P.R. Intrastriatal transplantation of rat adrenal chromaffin cells seeded on microcarrier beads promote long-term functional recovery in hemiparkinsonian rats. Exp Neurol 1998, 151:203-214.
34. Cherksey B.D., Sapirstein V.S., Geraci A.L. Adrenal chromaffin cells on microcarriers exhibit enhanced long-term functional effects when implanted into the mammalian brain. Neuroscience 1996, 75:657-664.
35. Bakay R.A., Raiser C.D., Stover N.P., Subramanian T., Cornfeldt M.L., Schweikert A.W., et al. Implantation of Spheramine in advanced Parkinson's disease (PD). Front Biosci 2004, 9:592-602.
36. Stover N.P., Watts R.L. Spheramine for treatment of Parkinson's disease. Neurotherapeutics 2008, 5:252-259.
37. Tatard V.M., Menei P., Benoit J.P., Montero-Menei C.N. Combining polymeric devices and stem cells for the treatment of neurological disorders: a promising therapeutic approach. Curr Drug Targets 2005, 6:81-96.
38. Tucker B.A., Rahimtula M., Mearow K.M. Integrin activation and neurotrophin signaling cooperate to enhance neurite outgrowth in sensory neurons. J Comp Neurol 2005, 486:267-280.
39. Hall P.E., Lathia J.D., Caldwell M.A., Ffrench-Constant C. Laminin enhances the growth of human neural stem cells in defined culture media. BMC Neurosci 2008, 9:71.
40. Kearns S.M., Scheffler B., Goetz A.K., Lin D.D., Baker H.D., Roper S.N., et al. A method for a more complete in vitro Parkinson's model: slice culture bioassay for modeling maintenance and repair of the nigrostriatal circuit. J Neurosci Methods 2006, 157:1-9.
41. Kearns S.M., Laywell E.D., Kukekov V.K., Steindler D.A. Extracellular matrix effects on neurosphere cell motility. Exp Neurol 2003, 182:240-244.
42. Qian L., Saltzman W.M. Improving the expansion and neuronal differentiation of mesenchymal stem cells through culture surface modification. Biomaterials 2004, 25:1331-1337.
43. Ho M., Yu D., Davidsion M.C., Silva G.A. Comparison of standard surface chemistries for culturing mesenchymal stem cells prior to neural differentiation. Biomaterials 2006, 27:4333-4339.
44. Nakajima M., Ishimuro T., Kato K., Ko I.K., Hirata I., Arima Y., et al. Combinatorial protein display for the cell-based screening of biomaterials that direct neural stem cell differentiation. Biomaterials 2007, 28:1048-1060.
45. Tatard V.M., Venier-Julienne M.C., Saulnier P., Prechter E., Benoit J.P., Menei P., et al. Pharmacologically active microcarriers: a tool for cell therapy. Biomaterials 2005, 26:3727-3737.
46. Bouffi C., Thomas O., Bony C., Giteau A., Venier-Julienne M.C., Jorgensen C., et al. The role of pharmacologically active microcarriers releasing TGF-beta3 in cartilage formation in vivo by mesenchymal stem cells. Biomaterials 2010, 31:6485-6493.
47. Tatard V.M., Venier-Julienne M.C., Benoit J.P., Menei P., Montero-Menei C.N. In vivo evaluation of pharmacologically active microcarriers releasing nerve growth factor and conveying PC12 cells. Cell Transplant 2004, 13:573-583.
48. Tatard V.M., Sindji L., Branton J.G., Aubert-Pouessel A., Colleau J., Benoit J.P., et al. Pharmacologically active microcarriers releasing glial cell line - derived neurotrophic factor: survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats. Biomaterials 2007, 28:1978-1988.
49. D'Ippolito G., Diabira S., Howard G.A., Menei P., Roos B.A., Schiller P.C. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004, 117:2971-2981.
50. D'Ippolito G., Diabira S., Howard G.A., Roos B.A., Schiller P.C. Low oxygen tension inhibits osteogenic differentiation and enhances stemness of human MIAMI cells. Bone 2006, 39:513-522.
51. Tamama K., Kawasaki H., Wells A. Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol 2010, 795385.
52. Padovan C.S., Jahn K., Birnbaum T., Reich P., Sostak P., Strupp M., et al. Expression of neuronal markers in differentiated marrow stromal cells and CD133+ stem-like cells. Cell Transplant 2003, 12:839-848.
53. Freire E., Gomes F.C., Linden R., Neto V.M., Coelho-Sampaio T. Structure of laminin substrate modulates cellular signaling for neuritogenesis. J Cell Sci 2002, 115:4867-4876.
54. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. RESEARCH0034.
55. Giteau A., Venier-Julienne M.C., Marchal S., Courthaudon J.L., Sergent M., Montero-Menei C., et al. Reversible protein precipitation to ensure stability during encapsulation within PLGA microspheres. Eur J Pharm Biopharm 2008, 70:127-136.
56. Fraker P.J., Speck J.C. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978, 80:849-857.
57. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152:259-277.
58. Horwitz E.M., Prather W.R. Cytokines as the major mechanism of mesenchymal stem cell clinical activity: expanding the spectrum of cell therapy. Isr Med Assoc J 2009, 11:209-211.
59. Chen Q., Long Y., Yuan X., Zou L., Sun J., Chen S., et al. Protective effects of bone marrow stromal cell transplantation in injured rodent brain: synthesis of neurotrophic factors. J Neurosci Res 2005, 80:611-619.
60. Ohtaki H., Ylostalo J.H., Foraker J.E., Robinson A.P., Reger R.L., Shioda S., et al. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci U S A 2008, 105:14638-14643.
61. Docheva D., Popov C., Mutschler W., Schieker M. Human mesenchymal stem cells in contact with their environment: surface characteristics and the integrin system. J Cell Mol Med 2007, 11:21-38.
62. Lu P., Blesch A., Tuszynski M.H. Induction of bone marrow stromal cells to neurons: differentiation, transdifferentiation, or artifact?. J Neurosci Res 2004, 77:174-191.
63. Khoo M.L., Shen B., Tao H., Ma D.D. Long-term serial passage and neuronal differentiation capability of human bone marrow mesenchymal stem cells. Stem Cells Dev 2008, 17:883-896.
64. Sensebe L., Deschaseaux M., Li J., Herve P., Charbord P. The broad spectrum of cytokine gene expression by myoid cells from the human marrow microenvironment. Stem Cells 1997, 15:133-143.
65. Hurelbrink C.B., Barker R.A. The potential of GDNF as a treatment for Parkinson's disease. Exp Neurol 2004, 185:1-6.
66. Garbayo E., Montero-Menei C.N., Ansorena E., Lanciego J.L., Aymerich M.S., Blanco-Prieto M.J. Effective GDNF brain delivery using microspheres - a promising strategy for Parkinson's disease. J Control Release 2009, 135:119-126.
67. Jollivet C., Aubert-Pouessel A., Clavreul A., Venier-Julienne M.C., Remy S., Montero-Menei C.N., et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials 2004, 25:933-942.
68. Bjorklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997, 4:186-200.
69. Block G.J., Ohkouchi S., Fung F., Frenkel J., Gregory C., Pochampally R., et al. Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem Cells 2009, 27:670-681.